- What is the Evidence to Contraindicate Breast-Feeding of an Infant whose Mother is on Platinum Based Chemotherapy?2012 | Central Library of Charles University
- BRCA mutation carriers suffering from ovarian cancer as a model for treatment decision in higher lines - Place for platinum reinduction2023 | First Faculty of Medicine, Third Faculty of Medicine
- A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer2008 | Third Faculty of Medicine
- Autologous dendritic cell-based immunotherapy (DCVAC/LuCa) and carboplatin/paclitaxel in advanced non-small cell lung cancer: A randomized, open-label, phase I/II trial2021 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Pilsen
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasePublication without faculty affiliation
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian CancerPublication without faculty affiliation
- The role of immunotherapy in the treatment of urothelial carcinoma2022 | First Faculty of Medicine
- Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: Report of two cases2012 | Faculty of Medicine in Hradec Králové
- Strategies for the treatment of urothelial carcinoma2023 | First Faculty of Medicine
- First-line treatment for non-squamous NSCLC without driver mutations2022 | Third Faculty of Medicine
- Advances in oncological treatment of head and neck tumors2018 | First Faculty of Medicine, Third Faculty of Medicine
- Niraparib2021 | First Faculty of Medicine
- Nivolumab as second-line therapy for patients with advanced NSCLC (non-small cell lung cancer)2022 | First Faculty of Medicine
- Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial2023 | First Faculty of Medicine
- The association of taxane resistance genes with the clinical course of ovarian carcinoma2013 | First Faculty of Medicine, Second Faculty of Medicine
- Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis2022 | First Faculty of Medicine
- Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non-Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy2010 | Third Faculty of Medicine
- Molecular biology of testicular germ cell tumors: Unique features awaiting clinical application2014 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Physical Education and Sport
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial2020 | First Faculty of Medicine
- Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment2021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Pilsen
- NSCLC (Non-Small Cell Lung Cancer) and kidney tumor in the elderly patient with response to chemoimmunotherapy2021 | First Faculty of Medicine
- Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)2010 | Third Faculty of Medicine
- Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?2023 | First Faculty of Medicine
- Positron emission tomography and histology of residual postchemotherapy masses in patients with nonseminomatous germ cell tumours2012 | First Faculty of Medicine, Third Faculty of Medicine
- Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer2023 | Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen
- Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study2023 | Faculty of Medicine in Pilsen
- Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial2015 | First Faculty of Medicine
- Olaparib combined with chemotherapy for recurrent platinum - sensitive ovarian cancer : a randomised phase 2trial2015 | Publication without faculty affiliation
- Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial2022 | First Faculty of Medicine
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL2009 | Third Faculty of Medicine